OR WAIT 15 SECS
Patients with a hereditary form of emphysema caused by alpha-1 proteinase inhibitor (A1PI) deficiency now have another therapeutic option. The FDA recently approved alpha1-proteinase inhibitor (human) [Aralast, Baxter] for chronic augmentation therapy in patients having congenital deficiency of A1PI with clinically evident emphysema. Aralast is currently available exclusively through the specialty pharmacy providers Accredo Health, Caremark, and Coram Healthcare. To obtain more information about Aralast, contact Baxter at (800) 423-2090.